Desensitization with High-Dose IVIg for Highly Sensitized Candidates Awaiting Deceased-Donor Kidney Transplantation: Transplant Access and Long-Term Outcomes
Medical Research Archives · 30.09.2026 · 14 (9)
DOI: 10.18103/mra.2026.0602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 30.09.2026. Verfasst von Jenaine Oliveira Paixão und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Highly sensitized (HS) patients remain longer on the waiting list, presenting high mortality and morbidity rates, especially where there is no specific allocation system. The reduction of anti-HLA antibodies, using only IVIg has already proved to be efficient and safe for living donor transplantation. The results of adopting only IVIg to increase access to transplant with deceased donors in sensitized patients are shown here. We evaluated sensitized patients, waiting for a deceased donor, and presenting many positive T and/or B-cell CDC-XM on the WL, who underwent a desensitization (DS) protocol using only IVIg 2g/kg/month, and followed over 58,9 +- 22,9 months. Patients had been on renal replacement therapy for an average of 91 +- 60 months. Transplants were cleared with the first negative T and B-cell CDC-XM. Of the 45 patients who initiated the study 6 were excluded: 3 obtained a living donor and 3 did not complete the minimum of three consecutive IVIg doses. Of the remaining 39 patients, 14 (35.9%) were transplanted during the FUT, 9 (64.3%) presenting DSA. Mean time on the WL before DS was 75 +- 41 months and after DS initiation was 20 +- 11 months (p
Zitieren
APA
Paixão, J. O., Ulisses, L. R. S., Agena, F., Souza, P. S. D., Bezerra, G. O., Rodriges, H., David-Neto, E., & Castro, M. C. R. D. (2026). Desensitization with High-Dose IVIg for Highly Sensitized Candidates Awaiting Deceased-Donor Kidney Transplantation: Transplant Access and Long-Term Outcomes. Medical Research Archives, 14(9). https://doi.org/10.18103/mra.2026.0602
Vancouver
Paixão JO, Ulisses LRS, Agena F, Souza PSD, Bezerra GO, Rodriges H, et al. Desensitization with High-Dose IVIg for Highly Sensitized Candidates Awaiting Deceased-Donor Kidney Transplantation: Transplant Access and Long-Term Outcomes. Medical Research Archives. 2026;14(9). doi:10.18103/mra.2026.0602
BibTeX
@article{Paixo2026,
author = {Paixão, Jenaine Oliveira and Ulisses, Luiz Roberto S and Agena, Fabiana and Souza, Patricia Soares de and Bezerra, Gislene Oliveira and Rodriges, Helcio and David-Neto, Elias and Castro, Maria Cristina Ribeiro de},
title = {Desensitization with High-Dose IVIg for Highly Sensitized Candidates Awaiting Deceased-Donor Kidney Transplantation: Transplant Access and Long-Term Outcomes},
journal = {Medical Research Archives},
year = {2026},
volume = {14},
number = {9},
doi = {10.18103/mra.2026.0602}
}
EUVIMED